Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis
about
Second-generation antipsychotics and extrapyramidal adverse effectsAtypical antipsychotics for psychosis in adolescentsAtypical antipsychotics for psychosis in adolescentsTypical antipsychotics for psychosis in adolescentsEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisEffects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical updateAssociation of typical versus atypical antipsychotics with symptoms and quality of life in schizophreniaExploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinThe developing utility of zebrafish models for cognitive enhancers researchEffectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library.Increased Silent Brain Infarction Accompanied With High Prevalence of Diabetes and Dyslipidemia in Psychiatric Inpatients: A Cross-Sectional Study.Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonCariprazine in the treatment of schizophrenia: a proof-of-concept trialTreatment Response in First-episode Schizophrenia.Atypical antipsychotic medications and hyponatremia in older adults: a population-based cohort study.A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand.Lipid profile in antipsychotic drug users: A comparative study.Caenorhabditis elegans as a model for obesity research.Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.Examining the effectiveness of antipsychotic medication in first-episode psychosis.Electroencephalogram-based pharmacodynamic measures: a review.Atypical antipsychotics: trends in analysis and sample preparation of various biological samples.Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.Pharmacological approaches to the management of schizophrenia: 10 years on.Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Translational Value of Drug Discrimination with Typical and Atypical Antipsychotic Drugs.Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?Choosing to use compared to taking medication: the meaning of medication as described by people who experience schizophrenia.Meaning of resilience as described by people with schizophrenia.Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: a cross-sectional study.Social and clinical descriptors of antipsychotic prescription.Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice.Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia.Effectiveness of adherence therapy in patients with early psychosis: a mirror image study.
P2860
Q21284676-37F6D1B8-E7D0-452C-B7C8-5BBCB71BBE4DQ24197475-E9C6287C-B919-440E-AC72-A0AB43BE77F8Q24203954-F7CACCCD-B3D5-452C-8FDC-A911E25C8C48Q24203964-A6A8EC1C-3383-445A-BF0F-50FF4A62F913Q24606868-1D08FDEA-CDD6-4A4C-8C1E-B548219F618AQ26823735-2C11193E-D7FA-41B0-BF10-B31879E6A5C3Q28483750-B24BA0EE-1B2B-4682-862D-29F1E918140AQ30427775-F7F1D952-6947-41A2-B427-2E370963E1FBQ30457705-88EF2E2E-4AFD-4846-A50F-43EC46DC05E5Q30490166-2988086E-B78D-4D4E-905E-58F83801BA4CQ34631699-5E21F0A0-3298-4046-8DAA-19643F4B669CQ35213673-2B14309F-D44A-4EDC-BE59-873D90D18F81Q36028257-8A2E68E6-AE32-4331-8D5A-24F3FC7FF266Q36325431-CE6CAE10-1525-440C-8E6B-9BDE476B12B7Q36530048-89A9012A-C4C9-4272-B79C-AED32589137AQ36600801-C456E739-ED63-4136-BEE6-DE3C674BBAB4Q36785625-43A77ED8-E61A-4EBF-8D19-BD9A5936EA89Q36852406-269912A5-043D-4DDA-A1AF-A62549DDAC67Q36872731-8966D729-7CB7-45E2-96A1-4A45A88A7231Q36925516-79B76856-3E41-436E-AFD8-A035ED799845Q37873726-266BD40D-9684-4555-A698-4C61E5D61C0CQ37953186-1BFC4244-E150-4F5D-9AB5-2FE29648AB06Q37984274-F831997A-AB96-4B6F-8B73-6B4615A87874Q37989009-0F8EE1E9-2E48-4DD7-AE2A-C8560196B138Q38005440-A387DB65-567A-43C9-948B-DA7E924B9EF0Q38076126-0DAA6092-21EA-4362-B832-79990D63DB01Q38100731-3EC95CF5-6DAB-428E-A9B8-620A3E92EA45Q38101540-99A8FB4D-B307-4C76-9C5D-584DF170B2F0Q38592404-78B5B6A1-8D7E-4D3C-AAF7-6262ABCCDF5AQ38697025-840D6892-B770-43EA-A865-5DABAF11F84DQ38877181-7F8E0B34-21F0-48A0-8B43-C3FAED4867D3Q39158338-D68DC697-06D4-4339-9671-73421BA4A5A0Q39264607-C0BEEED2-2F49-41A9-931A-7CC658634DBBQ39299741-7E851B38-D9A4-4DAE-81A6-245566D8B389Q39432209-E97EBD5C-DA34-4928-B2D8-591A88A5970EQ39726164-0DF89C09-9A84-4302-AA36-BD217B18DAA0Q40269113-6EFB510F-A2D5-4634-83A2-335D36578468Q41994722-792B779D-98D7-4192-AFDB-E772FE43F726Q42380356-81C4CE01-850A-468D-8548-3F5CB0206AB9Q44616517-93FA343C-EFF7-4EAC-BC93-00737F929EC0
P2860
Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@ast
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@en
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@nl
type
label
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@ast
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@en
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@nl
prefLabel
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@ast
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@en
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@nl
P2860
P3181
P1476
Efficacy of atypical v. typica ...... early psychosis: meta-analysis
@en
P2093
Miguel Constante
Paddy Power
P2860
P3181
P356
10.1192/BJP.BP.109.066217
P407
P577
2010-06-01T00:00:00Z